BioClinica says increasing interest in CNS disorders will drive the imagining sector; and predicts that pharmas and CROs will want integrated EDC in two years.
Non-profit epilepsy research sponsor, Epilepsy Therapy Project (ETP), has announced it is to invest in central nervous system (CNS) drug delivery specialist, ICVrx, to support the development of novel drug tech designed to tackle refractory epilepsy.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Hemispherx Biopharma, Novartis and InVivo.
Nose-to-brain delivery can become a reality, even for molecules with high molecular weights, but barriers relating to administration and adsorption remain, according to a panel at AAPS.
Alnylam Pharmaceuticals, Medtronic and CHDI Foundation are collaborating to advance RNAi delivered by an implantable infusion device for treating Huntingdon’s.
Genzyme is evaluating to-BBB’s G-Technology as part of a research collaboration aimed at developing treatments capable of crossing the blood-brain barrier (BBB).
Orasi Medical claims CROs and pharmas can cut the cost and length of Alzheimer’s trials, and improve accuracy, by using its brain function measuring service, which is now being promoted in Japan.
Finnish drugmaker Orion is to follow through on plans to cut its R&D workforce and shed 205 employees to sure up operations as generic pressure mounts on its leading Parkinson’s disease drugs.
Kendle has posted a sprightly 30 per cent increase in service revenues in the second quarter, bringing in $127m, well ahead of forecasts and providing further evidence of the buoyancy of the contract research market.
Brookwood Pharmaceuticals, a subsidiary of SurModics, has acquired the exclusive rights to all pharmaceutical applications of PharmaSol’s nanostructured lipid carrier (NLC) technology.
A novel technology set to overcome the challenges of the blood
brain barrier is being developed in a bid to open the gates to
previously unusable compounds for the treatment of central nervous
system (CNS) disorders.
Anglo-German firm Evotec is taking its fragment-based drug
discovery (FBDD) services a step further with the launch today of a
new innovation centre for FBDD.
Pharma company Medichem has announced it has passed a US Food and
Drug Administration (FDA) inspection without any problem for the
third consecutive time.
According to a new report, the European central nervous system
therapeutic market is set to capitalise on an ageing population, a
high level of unmet clinical need and increasing prevalence of
neurological disorders, growing to $31.31bn...
GlaxoSmithKline (GSK) has created a Centre of Excellence for
External Drug Discovery (CEEDD) that aims to provide GSK with
alternative scientific and drug discovery approaches. The CEEDD
also aims to exploit the full potential of...
France's Valois has developed a new type of dose dispensing pump
which allows intranasal formulations of drugs to be created that do
not require the use of preservatives, reports Phil Taylor.
Efforts to improve the efficacy of cancer therapy by blocking
cellular mechanisms that underlie resistance to cytotoxic drugs
have promised much but delivered little to date. Now, a team of
researchers in the US believe they have...
Scientists who have discovered the binding site for the
anti-epilepsy drug Keppra have confirmed that the drugs mechanism
of action places it in a new class of central nervous system (CNS)
drugs.
A pilot project aimed at identifying new drug candidates for
central nervous system disorders, initiated by Germany's 4SC and
Spain's Esteve, has grown into a full-blown collaboration between
the companies.